Interpretable machine learning leverages proteomics to improve cardiovascular disease risk prediction and biomarker identification
Top Cited Papers
Open Access
- 19 May 2025
- journal article
- research article
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-12
Abstract
Background Cardiovascular diseases (CVDs) rank amongst the leading causes of long-term disability and mortality. Predicting CVD risk and identifying associated genes are crucial for prevention, early intervention, and drug discovery. The recent availability of UK Biobank Proteomics data enables investigation of blood proteins and their association with a variety of diseases. We sought to predict 10 year CVD risk using this data modality and known CVD risk factors. Methods We focused on the UK Biobank participants that were included in the UK Biobank Pharma Proteomics Project. After applying exclusions, 50,057 participants were included, aged 40–69 years at recruitment. We employed the Explainable Boosting Machine (EBM), an interpretable machine learning model, to predict the 10 year risk of primary coronary artery disease, ischemic stroke or myocardial infarction. The model had access to 2978 features (2923 proteins and 55 risk factors). Model performance was evaluated using 10-fold cross-validation. Results The EBM model using proteomics outperforms equation-based risk scores such as PREVENT, with a receiver operating characteristic curve (AUROC) of 0.767 and an area under the precision-recall curve (AUPRC) of 0.241; adding clinical features improves these figures to 0.785 and 0.284, respectively. Our models demonstrate consistent performance across sexes and ethnicities and provide insights into individualized disease risk predictions and underlying disease biology. Conclusions In conclusion, we present a more accurate and explanatory framework for proteomics data analysis, supporting future approaches that prioritize individualized disease risk prediction, and identification of target genes for drug development.Keywords
All Related Versions
This publication has 43 references indexed in Scilit:
- Metabolomic and genomic prediction of common diseases in 700,217 participants in three national biobanksNature Communications, 2024
- Plasma proteomic associations with genetics and health in the UK BiobankNature, 2023
- Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular EventsJAMA, 2023
- New Way to “SCORE” Risk: Updates on the ESC Scoring System and Incorporation into ESC Cardiovascular Prevention GuidelinesCurrent Cardiology Reports, 2022
- Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosisNature Reviews Cardiology, 2021
- GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic diseaseNature Reviews Endocrinology, 2021
- The changing landscape of atherosclerosisNature, 2021
- The UK Biobank resource with deep phenotyping and genomic dataNature, 2018
- Anti-inflammatory therapeutics for the treatment of atherosclerosisNature Reviews Drug Discovery, 2011
- Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studiesThe Lancet, 2010